AVIEW LCS vs 1CMR Pro
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your institution requires a comprehensive AI solution for integrated cardiopulmonary assessment from a single low-dose CT scan. This tool is ideal for lung cancer screening programs that also benefit from concurrent, automated analysis of COPD and coronary artery calcification, streamlining workflows and generating comprehensive reports.
View AVIEW LCS →Choose 1CMR Pro if…
Choose 1CMR Pro if your cardiology department prioritizes highly precise and consistent AI-enhanced reporting specifically for Cardiac MRI studies. This on-premise solution delivers up to 40% more precise volumetric and functional measurements, ensuring local data processing and clinician control over editable contours for enhanced accuracy and reproducibility.
View 1CMR Pro →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | 1CMR Pro |
|---|---|---|
| Pricing | Subscription or one-off payment | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | On-premise (software installed on hospital's own computer, processing data locally via a secure web-based platform) |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS offers a wider range of deployment options (cloud, hybrid, local, virtualized) and emphasizes comprehensive workflow automation, including follow-up registration and nodule matching for serial CT scans. Its focus on automating tedious manual tasks and generating pre-populated reports suggests a more streamlined and integrated user experience across the entire screening and follow-up process.
Clinical Value
AVIEW LCSAVIEW LCS provides a comprehensive '3-in-1 solution' for the integrated detection and analysis of lung nodules, COPD, and coronary artery calcification from a single low-dose CT scan, offering broad diagnostic utility and efficiency in screening programs. Studies indicate it can reduce the likelihood of misidentifying nodules compared to human radiologists and significantly diminish radiologist workload. While 1CMR Pro offers impressive precision in cardiac MRI, AVIEW LCS's multi-disease screening approach from a single, common imaging modality offers a wider population health impact.
Pricing & Value
TieBoth tools require direct contact for pricing, and neither provides publicly disclosed pricing details. While AVIEW LCS offers some insight into its pricing model (one-off payment, subscription, based on installations/users), this is insufficient to conduct a meaningful head-to-head comparison of actual costs or value against 1CMR Pro, which remains entirely opaque.
Enterprise Readiness
AVIEW LCSAVIEW LCS explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), alongside offering highly flexible deployment options including cloud, hybrid, and various local setups. Although 1CMR Pro emphasizes local data processing, ISO 27001 certification, and EU AI Act compliance, it lacks an explicit HIPAA compliance statement or BAA confirmation, making Tool A more comprehensively enterprise-ready for diverse IT environments and regulatory requirements.
Innovation
AVIEW LCSAVIEW LCS demonstrates innovation through its integrated, fully automatic analysis of three major cardiopulmonary diseases (lung cancer, COPD, and coronary artery calcification) from a single low-dose CT scan, offering a holistic screening approach and automated comparison for follow-up scans. While 1CMR Pro's precision in cardiac MRI is highly innovative, AVIEW LCS's multi-disease integration for a common screening modality represents a broader, workflow-transforming innovation in population health.
Support & Docs
TieThe provided structured facts and web search results offer minimal information regarding the availability, breadth, or quality of support and documentation for either tool. While 1CMR Pro mentions a dedicated support email for access and sign-in help, this is insufficient to differentiate it from AVIEW LCS in terms of overall support and documentation quality.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | 1CMR Pro |
|---|---|---|
| Name | AVIEW LCS | 1CMR Pro |
| Company | Coreline Soft Co. | Mycardium AI Limited |
| Description | AI-powered solution for the detection and analysis of lung nodules. The AVIEW LCS Plus platform provides integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy and streamlining radiology workflows. | FDA 510(k) cleared and CE Class IIB cleared AI-enhanced Cardiac MRI reporting software that delivers up to 40% more precise measurements, enabling faster and more consistent cardiac MRI analysis. |
| Primary Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology, Radiology |
| Key Features (Examples) | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass) | AI-enhanced Cardiac MRI Reporting, Automated volumetric and functional measurements, Local data processing (no patient data transmitted beyond institution), Transparent and editable contours for clinician control, Achieves up to 40% higher precision than manual analysis |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and 1CMR Pro.